Microbio
Targeted Pathogen Identification for Early Sepsis Management
Sepsis is a serious and complex healthcare challenge where timely intervention is crucial. Effective treatment relies on the accurate identification of pathogens. However, standard of care methods such as blood culture often fail to provide results quickly enough for prompt early treatment. This delay in identifying pathogens negatively affects patient outcomes and increases the risk of antimicrobial resistance (AMR) due to the extended use of broad-spectrum antibiotics.
Challenges
InfectID™-BSI: Improving Standard of Care
InfectID™-BSI addresses the limitations of standard of care by using a direct molecular identification technique. While standard of care, including blood culture, remains necessary, InfectID™-BSI provides results within hours, enabling clinicians to make informed decisions for targeted therapy sooner.
InfectID™-BSI
A bloodstream infection (BSI) and sepsis pathogen identification blood test that requires no pre-culture.
Less than 3 hours laboratory time to actionable results
By delivering clinically relevant information in less than 3 hours, InfectID™-BSI empowers clinicians to initiate targeted antimicrobial therapies promptly, improving patient outcomes.
Identifies the top 20 bacterial and 6 yeast pathogens
Identifies the pathogens responsible for 94% of sepsis cases, providing more comprehensive results than the current standard of care.
Direct from whole blood
Achieve rapid results without delays from enrichment or culture, streamlining the diagnostic process.
qPCR molecular detection
Detects the unique genetic fingerprint of pathogens, avoiding limitations often associated with traditional culture-based methods.
Uses the melt curve feature of qPCR
Assays are multiplexed without compromising high accuracy.
Minimally invasive sampling
Validated with just 0.4 mL of blood, InfectID™-BSI is particularly beneficial for patients who have difficulty providing large blood samples.
Featured Products
About Microbio
Leading the paradigm shift in pathogen identification
Microbio is an Australian biotech leader which is making a difference in the battle to stop pathogens destroying lives—by arming clinicians with the tools they need to improve patient outcomes, and by developing new tools to counter the existential threat of antimicrobial resistance.
Why You Do Bio
Why Choose YouDoBio for Microbio Products in Scandinavia?
YouDoBio is Microbio’s dedicated distribution partner for customers in Denmark, Sweden, and Norway. We provide regional access to Microbio’s innovative pathogen identification solutions, including the InfectID™-BSI assay.
Our team is ready to assist laboratories and clinicians in Scandinavia with acquiring and integrating Microbio’s advanced diagnostic solutions to improve patient outcomes in sepsis management.
